SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as community members discuss Elon Musk's recent purchase of $1 billion in TSLA shares, which many see as a strong signal of confidence. The move has sparked discussions about a potential short squeeze and the stock's future trajectory, with some anticipating a continued rally while others remain skeptical of the company's fundamentals.

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is trending due to speculation surrounding a potential SOL treasury announcement and recent positive outcomes from their stroke study, leading to discussions about a possible short squeeze. Community members are actively debating the stock's potential for a significant run, drawing comparisons to other companies that have launched crypto treasury initiatives. However, concerns remain regarding the company's history of reverse splits and dilution.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as the community discusses potential catalysts like FAA certification and new partnerships, while also debating whether recent price action indicates a buying opportunity or further downside. Some speculate about government contracts and compare ACHR to competitors like $JOBY in the eVTOL space. Concerns about a short report and the CEO's communication are also prevalent.

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Tyler, TX.

NanoVibronix Inc

NanoVibronix is trending as traders discuss its low float and potential short squeeze, following news of a granted U.S. patent for pediatric feeding tube guidance. Community members are actively monitoring price levels and volume, with some anticipating a significant upward move, while others remain cautious due to the stock's history of reverse splits. Discussions also involve potential price targets and the impact of the new patent on the company's commercialization path.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending due to high volatility following its merger, with discussions focused on trading halts and the potential for a short squeeze. The community is debating the impact of a new share repurchase program and potential Bitcoin purchases, while also noting the CUSIP change affecting trading on some platforms. Overall, traders are closely watching the stock's price action and the potential for significant swings.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending due to a mix of bullish news, including a new $6.3B cloud capacity deal with Nvidia, and bearish sentiment from Kerrisdale Capital announcing a short position with a 90% downside target. The community is debating the impact of the Nvidia deal, potential UK data center investments, and whether the recent price action is setting up for a short squeeze or a further pullback. Discussions also revolve around insider selling and its effect on investor confidence.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc. is trending amidst discussions around its high short interest, potential for a short squeeze, and the upcoming launch of its Rumble Wallet. Some see the stock as a play on a shift in media and cloud services towards platforms valuing free speech, further fueled by the perceived support from prominent figures. Additionally, the possible acquisition of Northern Data and its impact on Rumble's cloud capacity is a hot topic.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics is trending following a licensing deal with Novartis to develop molecular glue degraders for immune-mediated diseases, potentially worth billions. The community is speculating about a possible bidding war for the company between Novartis and Roche. Discussions also revolve around the company's cash position and potential price target upgrades.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital ($APLD) is trending as investors celebrate news that a tenant, CoreWeave, signed a large order form with NVIDIA, signaling strong demand for data center capacity and AI infrastructure. The community is optimistic about APLD's prospects in the AI sector and anticipates further announcements regarding new partnerships and data center developments. Bullish sentiment is fueled by the potential for a short squeeze and the company's strategic positioning in the growing AI market.

Grab Holdings Ltd. engages in the provision of millions of people each day to access its driver- and merchant-partners to order food or groceries, send packages, hail a ride or taxi, pay for online purchases or access services such as lending, insurance, wealth management and telemedicine, all through a single “everyday everything” app. The firm operates in food deliveries and mobility and by TPV in the e-wallets segment of financial services in Southeast Asia. It operates across the deliveries, mobility and digital financial services sectors in eight countries namely: Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam. The company was founded by Anthony Tan Ping Yeow and Tan Hooi Ling in 2012 and is headquartered in Singapore.

Grab Holdings Limited - Ordinary Shares - Class A

Grab Holdings Limited

GRAB is trending due to positive sentiment around its potential for growth in Southeast Asia, particularly as it nears profitability, with community members on X discussing a possible merger and institutional buying. The stock is also seeing increased chatter after breaking out of a multi-year base, drawing comparisons to other high-growth narratives, and analysts are highlighting its attractive valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.

RARE Reports Positive Long-Term Data From Metabolic Disorder Study

Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.

Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline

Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains?

BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA

RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.

RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End

Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.

Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Shares of Ultragenyx and Mereo BioPharma slipped in after-hours trading Wednesday after the companies said they will continue their Phase 3 trial of UX143 (setrusumab) as initially planned, rather than ending it early as they had hoped.In after-hours trading on Wednesday, Mereo BioPharma dropped 38.8% to $1.80, while Ultragenyx fell 25.8% to $30.76.UX143 is a monoclonal antibody that inhibits sclerostin, a negative regulator of bone formation. It is being jointly developed by Ultragenyx and Mereo BioPharma.The Data Monitoring Committee (DMC) reviewed the Orbit study and found that the treatment’s safety profile appeared acceptable, recommending continuation to&nbsp;the final analysis.Final results from both the Orbit and Cosmic studies are expected to be released around the end of the year.The Orbit trial is testing UX143 in patients aged 5 to 25 with osteogenesis imperfecta, a condition characterized by brittle bones.&nbsp;Participants are receiving either the experimental treatment or a placebo, with the&nbsp;primary focus on&nbsp;the frequency of&nbsp;fractures.&nbsp;After the&nbsp;primary data is collected, all patients will move to open-label treatment.The Cosmic trial is running in parallel for children aged 2 to 7, comparing UX143 to standard bisphosphonate therapy.&nbsp;The study is also ongoing, with final results expected after patients&nbsp;have completed at least 18 months of treatment.On Stocktwits, retail sentiment for both&nbsp;<a href="https://stocktwits.com/symbol/MREO">Mereo BioPharma</a> and&nbsp;<a href="https://stocktwits.com/symbol/RARE">Ultragenyx</a> was tagged as ‘extremely bullish’ with ‘extremely high’ message volume.Some users&nbsp;suggested that the market was overreacting to the update from Mereo BioPharma and Ultragenyx, with one describing Mereo as a “good medium to long-term candidate” and another&nbsp;attributing the drop to a retail misunderstanding of standard clinical trial practices.<stembedurl>https://stocktwits.com/LogicalTrading/message/620417028</stembedurl><stembedurl>https://stocktwits.com/JCobb1/message/620403932</stembedurl>One comment noted that the final analysis will use a conventional 0.05 p-value threshold and expressed optimism about the chances of success, while an Ultragenyx watcher speculated the market was prematurely pricing in study failure.<stembedurl>https://stocktwits.com/RenHenInvestments/message/620415451</stembedurl><stembedurl>https://stocktwits.com/bhavn008/message/620395599</stembedurl>While Ultragenyx’s stock has risen 0.7% so far in 2025, Mereo’s stock&nbsp;has declined 14% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ultragenyx (RARE) and Mereo BioPharma (MREO) slipped in after-hours trading Wednesday after the companies said they will continue their Phase 3 trial of UX143 as initially planned/ Photo credit: Getty Images

Ultragenyx, Mereo Sink After Hours As Bone Drug Trial Continues Without Early Stop; Retail Traders Feel Selloff Is Overdone

Shares of Ultragenyx and Mereo BioPharma slipped in after-hours trading Wednesday after the companies said they will continue their Phase 3 trial of UX143 (setrusumab) as initially planned, rather than ending it early as they had hoped.

Equity

The companies now expect final data from the Orbit and Cosmic studies by the end of the year.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.23	--	--	N/A
Q2 '25	-$1.30	-$1.17	9.81%	BEAT
Q1 '25	-$1.60	-$1.57	1.74%	BEAT
Q4 '24	-$1.31	-$1.39	-6.23%	MISSED
Q3 '24	-$1.48	-$1.40	5.66%	BEAT

RARE
Ultragenyx Pharmaceutical Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest RARE News

RARE Ultragenyx Pharmaceutical Inc.